The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as a part of your standard-of-care (SOC).
Signed informed consent must be obtained prior to participation in the study.
Males aged ≥18 years.
ECOG performance status ≤ 1
Histologically confirmed adenocarcinoma of the prostate in a patient amenable to radical prostatectomy
Known allergies, hypersensitivity, or intolerance to 18F-flotufolastat.
Unable to receive androgen deprivation therapy.
Prostate cancer with significant neuroendocrine or other rare variant pathology
Evidence of metastatic disease involving bone, viscera, or lymph nodes superior to the bifurcation of the common iliac arteries on PSMA PET/CT
Baptist Health South Florida
Lead sponsor
Blue Earth Diagnostics
Collaborator